美国 · SEC FORM 4
Pyxis Oncology, Inc.
PYXS · Nasdaq · CIK 0001782223 · Healthcare · Biotechnology
内部人信号
1 qualifying P purchase group
当前 180 天评分窗口
3 同一窗口内观察到的 Form 4 交易行
1 sales · 1 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度与集中度
Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-10-01 · Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LP.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 4,886,652
- 上期报告
- 4,678,522
- 日均成交量
- 1,207,832
- 回补天数
- 4.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LP | 买入 (P) | Common Stock, par value $0.001 per share ("Common Stock") | 5,517,000 | USD — | USD — | SEC 申报 ↗ |
| 2024-11-26 | Connealy Pamela Ann | 买入 (P) | Common Stock | 88,850 | USD 1.96 | USD 174,364 | SEC 申报 ↗ |
| 2023-09-28 | Connealy Pamela Ann | 买入 (P) | Common Stock | 8,000 | USD 1.87 | USD 14,960 | SEC 申报 ↗ |
| 2023-09-27 | Wadhane Jitendra | 买入 (P) | Common Stock | 2,500 | USD 1.87 | USD 4,675 | SEC 申报 ↗ |
| 2023-09-27 | Connealy Pamela Ann | 买入 (P) | Common Stock | 6,426 | USD 1.85 | USD 11,888 | SEC 申报 ↗ |
| 2023-09-25 | Wadhane Jitendra | 买入 (P) | Common Stock | 5,000 | USD 1.77 | USD 8,850 | SEC 申报 ↗ |
| 2023-09-25 | Connealy Pamela Ann | 买入 (P) | Common Stock | 12,000 | USD 1.67 | USD 20,040 | SEC 申报 ↗ |
| 2023-09-22 | Wadhane Jitendra | 买入 (P) | Common Stock | 2,500 | USD 1.74 | USD 4,350 | SEC 申报 ↗ |
| 2023-09-22 | Connealy Pamela Ann | 买入 (P) | Common Stock | 5,000 | USD 1.74 | USD 8,700 | SEC 申报 ↗ |
| 2023-03-17 | PFIZER INC; Pfizer Ventures (US) LLC | 买入 (P) | Common Stock, $0.001 par value per share | 1,811,594 | USD 2.76 | USD 4,999,999 | SEC 申报 ↗ |
| 2023-03-17 | PFIZER INC; Pfizer Ventures (US) LLC | 买入 (P) | Common Stock, $0.001 par value per share | 1,811,594 | USD 2.76 | USD 4,999,999 | SEC 申报 ↗ |
| 2021-12-08 | Cline Darren S | 买入 (P) | Common Stock | 10,000 | USD 9.39 | USD 93,900 | SEC 申报 ↗ |
| 2021-11-18 | Civik Thomas | 买入 (P) | Common Stock | 15,700 | USD 12.74 | USD 200,018 | SEC 申报 ↗ |
| 2021-10-13 | Chin Mark | 买入 (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2021-10-13 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund III LP | 买入 (P) | Common Stock | 450,000 | USD 16.00 | USD 7,200,000 | SEC 申报 ↗ |
Form 4 申报证据
4 transaction lines in the latest 365-day window; 71 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LP | 买入 (P) | Common Stock, par value $0.001 per share ("Common Stock") | 5,517,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-30 | Dupont Jakob | 卖出 (S) | Common Stock | 35,000 | USD 3.06 | USD 107,100 | SEC 申报 ↗ |
| 2026-06-30 | Dupont Jakob | 期权行权／转换 (M) | Common Stock | 35,000 | USD 1.60 | USD 56,000 | SEC 申报 ↗ |
展开近期 Form 4 证据 (4 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LP | 买入 (P) | Common Stock, par value $0.001 per share ("Common Stock") | 5,517,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-30 | Dupont Jakob | 卖出 (S) | Common Stock | 35,000 | USD 3.06 | USD 107,100 | SEC 申报 ↗ |
| 2026-06-30 | Dupont Jakob | 期权行权／转换 (M) | Common Stock | 35,000 | USD 1.60 | USD 56,000 | SEC 申报 ↗ |
| 2026-03-24 | Wadhane Jitendra | 奖励／授予 (A) | Common Stock | 109,461 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PYXS |
| CIK | 0001782223 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 71 transaction lines from 2021-10-07 to 2026-10-01 16 P purchase lines · 10 S sale lines · 45 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.